Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

nd are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, incl
'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... chain in China based on the number ... 2014 Annual General Meeting of Shareholders (the "AGM") on October 22, ... at the meeting room of the Company at 6th Floor, Tower ... , Guangdong Province 518054, People,s ...
(Date:9/19/2014)... YORK , Sept. 19, 2014 Harwood ... against the board of directors of PDL BioPharma, Inc. ... concerning whether the board has breached its fiduciary duties ... On September 16, 2014, the Company disclosed: "On ... independent registered accounting firm, Ernst & Young LLP ("EY"), ...
(Date:9/19/2014)... 2014 "Copay coupons," a drug ... brand drugs among patients with prescription drug coverage, may now ... new report  from the Department of Health ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... by the federal government. The ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2
... Oct. 13, 2011 CVS Caremark (NYSE: CVS ... new partnership to identify, inspire and prepare young Latinos to ... of the prestigious HHF Youth Awards program. This fall and ... outstanding high school seniors of Latino descent for their academic ...
... Pharmaceutical Company (the "Company") (NYSE: KV.A/KV.B) appreciates that ... and Society for Maternal-Fetal Medicine (SMFM) have issued ... and the payer community have the facts regarding ... ACOG and SMFM statements regarding Makena were not ...
Cached Medicine Technology:CVS Caremark Partners With Hispanic Heritage Foundation to Identify and Inspire Future Latino Health Care Leaders 2CVS Caremark Partners With Hispanic Heritage Foundation to Identify and Inspire Future Latino Health Care Leaders 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
(Date:9/22/2014)... anxiety, excessive perspiration these symptoms are a few ... the body,s heart rate and plays a crucial role ... from Tel Aviv University points to an additional complication ... published in Mammalian Genome , was conducted by ... the Department of Human Molecular Genetics and Biochemistry at ...
(Date:9/22/2014)... leadership of Senators Sherrod Brown (D-Ohio) and Patty ... care services were lauded yesterday by the American ... representing internal medicine and related subspecialties. A ... introducing the Ensuring Access to Primary Care for ... extend current-law payment rates under Medicaid for certain ...
(Date:9/22/2014)... is one of 11 collaborating institutions that have been ... National Science Foundation for a project focused ... include plant symbionts, animal and human pathogens and decomposers ... used in numerous industrial processes and fermentation of foods, ... Symbiotic associations with zygomycetes may have facilitated the origin ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Broad physician coalition urges Congress to extend Medicaid pay parity 2Health News:Project launched to study evolutionary history of fungi 2Health News:Project launched to study evolutionary history of fungi 3Health News:Project launched to study evolutionary history of fungi 4
... , REDWOOD CITY, Calif., June 2 Integromics, ... RealTime StatMiner(R) and Integromics Biomarker Discovery(TM) (IBD) for ... The resulting platform provides a uniform ... genomics data, and then identify relevant biological processes ...
... ... Isn,t Sexy, LLC announces an initiative to have all dentists screen their patients for both ... ... epidemic proportions in the United States, Snoring Isn,t Sexy, LLC announces an initiative to have ...
... ... HealthForumOnline (HFO), announces a new CE/CEU course entitled A Review ... and Coordination of Care of the Pain Patient to their extensive ... professionals, nurses and allied healthcare workers. While there is an ...
... (NYSE: SGP ) today announced that the ... the company,s Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) ... episodes associated with bipolar I disorder. The application ... The MAA for SYCREST includes data from the asenapine ...
... , LOS ANGELES, June 1 Neurosurgeons, brain tumor researchers ... Department of Neurosurgery will present a one-day conference, ... to 4:30 p.m. The free conference is designed for brain ... the Medical Center,s Harvey Morse Auditorium, 8700 Beverly Blvd., Los ...
... , Support of local communities in the Silicon Valley , ... one of the nation,s first and leading providers of kidney ... announced their participation at the National Kidney Foundation (NKF) walk ... event will be held Saturday, June 6 at Cityview Plaza ...
Cached Medicine News:Health News:Ingenuity and Integromics Offer Integration for Comprehensive Genomics Analysis 2Health News:Founder of Snoring Isn't Sexy, LLC Urges All Dentists to Screen Their Patients for Snoring and Obstructive Sleep Apnea 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 3Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 4Health News:Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder 2Health News:'Outsmarting Brain Tumors': Cedars-Sinai Researchers, Neurosurgeons and Other Experts Present Free Conference for Adult Brain Tumor Patients and Caregivers 2Health News:Satellite Healthcare Steps Out in San Jose 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: